Cargando…
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD)
OBJECTIVE: The CHIMES Study compared MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours. We aimed to verify if patient selection based on two prognostic factors (ie, stroke severity and time to treatment) improves detection of a treatment effect wit...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054909/ https://www.ncbi.nlm.nih.gov/pubmed/26291445 http://dx.doi.org/10.1111/jebm.12170 |
_version_ | 1782458684562997248 |
---|---|
author | Venketasubramanian, Narayanaswamy Lee, Chun Fan Wong, K. S. Lawrence Chen, Christopher L. H. |
author_facet | Venketasubramanian, Narayanaswamy Lee, Chun Fan Wong, K. S. Lawrence Chen, Christopher L. H. |
author_sort | Venketasubramanian, Narayanaswamy |
collection | PubMed |
description | OBJECTIVE: The CHIMES Study compared MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours. We aimed to verify if patient selection based on two prognostic factors (ie, stroke severity and time to treatment) improves detection of a treatment effect with MLC601. METHODS: Analyses were performed using data from the CHIMES Study, an international, randomized, placebo‐controlled, double‐blind trial comparing MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours. Three subgroups, that is, onset to treatment time (OTT) ≥48 hours; baseline National Institute of Health Stroke Scale (NIHSS) ≥10; both OTT ≥48 hours and baseline NIHSS ≥10, were analyzed using modified Rankin Scale (mRS) ≤1 and a composite endpoint of mRS ≤1, Barthel Index ≥95, and NIHSS ≤1 at month 3. RESULTS: Placebo response rates were lower (ie, worse natural outcome) among subgroups with prognostic factors. Conversely, MLC601 treatment effects were significantly higher in the subgroups with prognostic factors than for the entire cohort, being highest among patients with both OTT ≥48 hours and baseline NIHSS of 10 to 14: odds ratios of 2.18 (95% CI 1.02 to 4.65) for month 3 mRS ≤1 and 3.88 (95% CI 1.03 to 14.71) for the composite endpoint. CONCLUSIONS: : Patients who have moderately severe strokes and longer OTT demonstrate better treatment effects with MLC601. These factors can guide patient selection in future trials. |
format | Online Article Text |
id | pubmed-5054909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50549092016-10-19 The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) Venketasubramanian, Narayanaswamy Lee, Chun Fan Wong, K. S. Lawrence Chen, Christopher L. H. J Evid Based Med Articles OBJECTIVE: The CHIMES Study compared MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours. We aimed to verify if patient selection based on two prognostic factors (ie, stroke severity and time to treatment) improves detection of a treatment effect with MLC601. METHODS: Analyses were performed using data from the CHIMES Study, an international, randomized, placebo‐controlled, double‐blind trial comparing MLC601 to placebo in patients with ischemic stroke of intermediate severity in the preceding 72 hours. Three subgroups, that is, onset to treatment time (OTT) ≥48 hours; baseline National Institute of Health Stroke Scale (NIHSS) ≥10; both OTT ≥48 hours and baseline NIHSS ≥10, were analyzed using modified Rankin Scale (mRS) ≤1 and a composite endpoint of mRS ≤1, Barthel Index ≥95, and NIHSS ≤1 at month 3. RESULTS: Placebo response rates were lower (ie, worse natural outcome) among subgroups with prognostic factors. Conversely, MLC601 treatment effects were significantly higher in the subgroups with prognostic factors than for the entire cohort, being highest among patients with both OTT ≥48 hours and baseline NIHSS of 10 to 14: odds ratios of 2.18 (95% CI 1.02 to 4.65) for month 3 mRS ≤1 and 3.88 (95% CI 1.03 to 14.71) for the composite endpoint. CONCLUSIONS: : Patients who have moderately severe strokes and longer OTT demonstrate better treatment effects with MLC601. These factors can guide patient selection in future trials. John Wiley and Sons Inc. 2015-08 2015-09-21 /pmc/articles/PMC5054909/ /pubmed/26291445 http://dx.doi.org/10.1111/jebm.12170 Text en © 2015 The Authors Journal of Evidence‐Based Medicine Published by Wiley Publishing Asia Pty Ltd This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Venketasubramanian, Narayanaswamy Lee, Chun Fan Wong, K. S. Lawrence Chen, Christopher L. H. The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title_full | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title_fullStr | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title_full_unstemmed | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title_short | The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD) |
title_sort | value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the chimes study of mlc601 (neuroaid) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5054909/ https://www.ncbi.nlm.nih.gov/pubmed/26291445 http://dx.doi.org/10.1111/jebm.12170 |
work_keys_str_mv | AT venketasubramaniannarayanaswamy thevalueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT leechunfan thevalueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT wongkslawrence thevalueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT chenchristopherlh thevalueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT venketasubramaniannarayanaswamy valueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT leechunfan valueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT wongkslawrence valueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid AT chenchristopherlh valueofpatientselectionindemonstratingtreatmenteffectinstrokerecoverytrialslessonsfromthechimesstudyofmlc601neuroaid |